Salute e Benessere
Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease
Additionally, when combined with GLP-1 receptor agonists, ATR-258 avoids the critical shortcomings of current obesity and diabetes treatments by preventing the muscle loss typically associated with these therapies.
: " ."
The study will appear in the September 2025 issue of and includes co-authors from multiple leading institutions across Europe and Australia . The breakthrough is the result of a long-term academic and industry collaboration led by Atrogi, together with scientists from Karolinska Institutet , Stockholm University , the University of Copenhagen , University of Nottingham, Monash University, and the University of Queensland . A key contributor was Assistant Professor Shane Wright of Karolinska Institutet , a leading expert in G protein–coupled receptor (GPCR) signaling, who co-elucidated the GRK2-biased mechanism that underpins ATR-258's muscle-specific effects.
Key findings from the study include:
:
In the near term, Atrogi is advancing ATR-258 into Phase 2 clinical trials, which will evaluate its ability to deliver exercise-like benefits, including fat loss, improved muscle strength and function, and better metabolic control – both as a monotherapy and in combination with GLP-1 receptor agonists.
Atrogi AB is a Stockholm -based clinical-stage biotechnology company focused on developing first-in-class therapies that harness skeletal muscle signaling to treat metabolic diseases. Its lead candidate, ATR-258, is an oral GRK2-biased β2-agonist designed to safely stimulate muscle metabolism and preserve lean mass, offering a novel approach to treating diabetes, obesity, and muscle loss.
Atrogi's proprietary compound library, developed under the scientific leadership of Professor Tore Bengtsson , serves as the foundation for a broader platform aimed at discovering selective GPCR modulators across multiple disease areas. Learn more at www.atrogi.com and on LinkedIn.
View original content:https://www.prnewswire.co.uk/news-releases/atrogi-announces-cell-paper-highlighting-transformative-potential-of-muscle-targeted-therapy-in-metabolic-disease-302488159.html